Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells Coral O. OmeneJing WuKrystyna Frenkel PRECLINICAL STUDIES Open access 03 May 2011 Pages: 1279 - 1288
The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis Christopher M. CabelloSarah D. LamoreGeorg T. Wondrak PRECLINICAL STUDIES 06 May 2011 Pages: 1289 - 1301
Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells Zahid M. DelwarDimitrios AvramidisJuan Sebastian Yakisich PRECLINICAL STUDIES 10 May 2011 Pages: 1302 - 1310
Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest Won Ki KimJu-Hwa KimSungpil Yoon PRECLINICAL STUDIES 15 May 2011 Pages: 1311 - 1318
Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models Angela Maria Di FrancescoPaolo UbezioRiccardo Riccardi PRECLINICAL STUDIES 03 June 2011 Pages: 1319 - 1330
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice. Mohammad AbolhassaniAdeline GuaisLaurent Schwartz PRECLINICAL STUDIES 09 June 2011 Pages: 1331 - 1342
Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-Methylfunicone from Penicillium pinophilum and cisplatin Elisabetta BuomminoAnna De FilippisGiovanna Donnarumma PRECLINICAL STUDIES 09 June 2011 Pages: 1343 - 1351
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks Yu KataokaToru MukoharaHironobu Minami PRECLINICAL STUDIES 08 June 2011 Pages: 1352 - 1360
Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia Darya HabibiNadya OgloffChristopher J. Ong PRECLINICAL STUDIES 17 June 2011 Pages: 1361 - 1370
The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma Juliana RomaniniTânia R. MielckeMaria M. Campos PRECLINICAL STUDIES 14 June 2011 Pages: 1371 - 1378
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor Lih-Ching HsuDavid E. DurrantRay M. Lee PRECLINICAL STUDIES 08 June 2011 Pages: 1379 - 1388
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells Ansgar BrüningPetra BurgerIoannis Mylonas PRECLINICAL STUDIES 29 June 2011 Pages: 1389 - 1395
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors Martin Schmidt-HieberRobert DabrowskiIgor Wolfgang Blau PRECLINICAL STUDIES 13 July 2011 Pages: 1396 - 1403
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer Jinah ParkEunju ParkYung-Jue Bang PRECLINICAL STUDIES 01 July 2011 Pages: 1404 - 1412
Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis James L. FigarolaYehua WengSamuel Rahbar PRECLINICAL STUDIES 05 July 2011 Pages: 1413 - 1425
Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo Juan R. RodriguesJaime CharrisClaudia Abramjuk PRECLINICAL STUDIES 12 July 2011 Pages: 1426 - 1433
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL Jung Jin HwangYong Sook KimChoung-Soo Kim PRECLINICAL STUDIES 20 July 2011 Pages: 1434 - 1442
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis Ahmad RazaBlake A. JacobsonRobert Arthur Kratzke PRECLINICAL STUDIES 26 July 2011 Pages: 1443 - 1448
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells Chin-Shiu HuangShih-Chieh LyuMiao-Lin Hu PRECLINICAL STUDIES 09 August 2011 Pages: 1449 - 1459
Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines Timothy C. HoranMichael A. ZompaThilo S. Lange PRECLINICAL STUDIES 02 August 2011 Pages: 1460 - 1470
Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death Agata M. WasikMichael N. GandyJohn Gordon PRECLINICAL STUDIES 18 August 2011 Pages: 1471 - 1483
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines Stefania GiudiceLuisa BenassiCristina Magnoni PRECLINICAL STUDIES 01 September 2011 Pages: 1484 - 1492
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study Jens SamolMalcolm RansonJames Cassidy PHASE I STUDIES 18 May 2011 Pages: 1493 - 1500
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy Sang Joon ShinMinkyu JungJoong Bae Ahn PHASE I STUDIES 13 May 2011 Pages: 1501 - 1510
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer Taroh SatohKensei YamaguchiHideyuki Mishima PHASE I STUDIES 25 May 2011 Pages: 1511 - 1518
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152) Ron J. KeizerAnthe S. ZandvlietAlwin D. R. Huitema PHASE I STUDIES Open access 28 May 2011 Pages: 1519 - 1530
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer Jean-Philippe SpanoMalcolm J. MooreOlivier Rixe PHASE I STUDIES 14 June 2011 Pages: 1531 - 1539
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma Su Jin LeeJeeyun LeeHo Yeong Lim PHASE I STUDIES 22 June 2011 Pages: 1540 - 1547
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer Yasushi GotoIkuo SekineTomohide Tamura PHASE I STUDIES Open access 13 July 2011 Pages: 1548 - 1556
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies Maarten J. DeenenHeinz-Josef KlümpenJohanna W. Wilmink PHASE I STUDIES Open access 02 August 2011 Pages: 1557 - 1565
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors Elisabeth I. HeathKaren FormanPatricia LoRusso PHASE I STUDIES 03 August 2011 Pages: 1566 - 1574
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies Athanassios ArgirisTrevor M. FeinsteinAnn Marie Egloff PHASE I STUDIES 01 September 2011 Pages: 1575 - 1584
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus Kuai-le ZhaoXi-chun HuGuo-Liang Jiang PHASE I STUDIES 08 September 2011 Pages: 1585 - 1590
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy Ramesh K. RamanathanJoe J. StephensonDonald A. Richards PHASE I STUDIES 24 August 2011 Pages: 1591 - 1596
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma Andrew H. KoHagop YoussoufianEric K. Rowinsky PHASE II STUDIES 01 June 2011 Pages: 1597 - 1606
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status Myoung Joo KangYong Sang HongTae Won Kim PHASE II STUDIES 25 June 2011 Pages: 1607 - 1613
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer Jason E. FarisJamie ArnottEunice L. Kwak PHASE II STUDIES 29 July 2011 Pages: 1614 - 1620
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer Ken KatoKeisho ChinRyuji Ikeda PHASE II STUDIES 05 July 2011 Pages: 1621 - 1627
Feasibility and effectiveness of inhaled carboplatin in NSCLC patients Paul ZarogoulidisEllada EleftheriadouKostantinos Zarogoulidis PHASE II STUDIES 08 July 2011 Pages: 1628 - 1640
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil Valerie FlorinEve DesmedtLaurent Mortier PHASE II STUDIES 13 July 2011 Pages: 1641 - 1645
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma Anthony B. El-KhoueiryCathryn J. RankinCharles D. Blanke PHASE II STUDIES 12 July 2011 Pages: 1646 - 1651
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer Emma K. BeardsleySebastien J. HotteKim N. Chi PHASE II STUDIES 23 July 2011 Pages: 1652 - 1659
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma Wayne L. FurmanLisa M. McGregorVictor M. Santana PHASE II STUDIES 28 July 2011 Pages: 1660 - 1670
Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer Byung Woog KangJong Gwang KimWansik Yu PHASE II STUDIES 17 August 2011 Pages: 1671 - 1675
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors J. Paul MonkMiguel Villalona-CaleroMartee L. Hensley PHASE II STUDIES 09 August 2011 Pages: 1676 - 1683
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction David J. AdelsteinCristina P. RodriguezThomas W. Rice PHASE II STUDIES 24 August 2011 Pages: 1684 - 1689
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer Yasuhide YamadaTatsuro YamaguchiYasuhiro Shimada PHASE II STUDIES 06 September 2011 Pages: 1690 - 1696
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis Annie BrionFaezeh LegrandEric Deconinck SHORT REPORT 13 January 2011 Pages: 1697 - 1702
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure Changhoon YooMin-Hee RyuYoon-Koo Kang SHORT REPORT 14 January 2011 Pages: 1703 - 1708
Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines Yakini BrandyInnocent OnoniwuOladapo Bakare SHORT REPORT 18 January 2011 Pages: 1709 - 1714